Core Laboratories (CLB) Non-Current Deffered Revenue (2022 - 2026)

Core Laboratories' Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $28.2 million for Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue fell 3.53% year-over-year to $28.2 million in Q1 2026; TTM through Mar 2026 was $28.2 million, a 3.53% decrease from a year earlier, with the FY2025 full-year figure at $29.4 million, down 5.57% from the prior year.
• Non-Current Deffered Revenue eased to $28.2 million in Q1 2026 per CLB's latest filing, from $29.4 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $31.8 million in Q4 2022 and bottomed at $28.2 million in Q1 2026.
• The 5-year median for Non-Current Deffered Revenue is $30.4 million (2024), against an average of $30.2 million.
• Across the five-year window, Non-Current Deffered Revenue climbed 8.44% in 2024 and slipped 5.57% in 2025, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $31.8 million in 2022, then decreased by 3.99% to $30.5 million in 2023, then grew by 1.87% to $31.1 million in 2024, then fell by 5.57% to $29.4 million in 2025, then fell by 4.14% to $28.2 million in 2026.
• Per Business Quant, the three latest CLB Non-Current Deffered Revenue figures stand at $28.2 million (Q1 2026), $29.4 million (Q4 2025), and $31.1 million (Q3 2025).